NK-1R antagonist

Phase 3Small molecule

PProf. Dr. Fridoon Jawad Ahmad

NK-1R antagonist is one of 39 small molecule programs targeting Respiratory Failure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory FailureActive, not recruiting

Respiratory FailurePhase 3

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Respiratory Failure

#DrugCompanyPhaseTrials

Diamox

Teva

Approved

1 2

Amidate

Pfizer

Approved

—3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

3 4

Decadron

AAspen Global Incorporated

Approved

1 5

Duragesic

CCephalon

Approved

1 6

Merrem

BB. Braun Medical Inc.

Approved

—7

Proair HFA

GGlaxo Dba Glaxosmithkline

Inomax

Versed

CConrado Roberto Hoffmann Filho

Approved

—10

Ketalar

AAultman Health Foundation

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Failure1 trial

To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients

Unknown status·PProf. Dr. Fridoon Jawad Ahmad·Phase 3·NCT04468646·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NK-1R antagonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NK-1R antagonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NK-1R antagonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prof. Dr. Fridoon Jawad Ahmad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PProf. Dr. Fridoon Jawad Ahmad

NK-1R antagonist

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Failure1 trial

References

Drug Info

Quick Facts

Related News